Iovance Biotherapeutics

Iovance Biotherapeutics

Iovance Biotherapeutics was founded in 2007 as a spinout from the National Cancer Institute, built around the clinical research of Dr. Steven Rosenberg. The firm's core asset is Amtagvi, the first and only FDA-approved T-cell therapy for a solid-tumor indication, which targets unresectable or metastatic melanoma. Frederick Vogt, who had served as General Counsel, was named interim CEO in early 2025 following a leadership transition. The firm's strategy concentrates on the development and commercialization of tumor-infiltrating lymphocyte therapies. Amtagvi is the flagship product, generating $128 million in product revenue during the first full quarter post-approval (per the firm, Q1 2025). The pipeline extends into non-small cell lung cancer and cervical cancer, with a combination therapy trial pairing TIL therapy with Merck's Keytruda actively enrolling. Iovance operates its own dedicated manufacturing facility in Philadelphia, a structural choice that gives it direct control over the notoriously complex TIL supply chain. Iovance reported a workforce of approximately 550 professionals across its California headquarters and Philadelphia cell therapy manufacturing center. The firm ended Q1 2025 with roughly $620 million in cash and equivalents, a runway intended to fund ongoing clinical development and commercial expansion. No family-office structure or adjacent private investment vehicles are associated with the entity; it operates as a publicly traded commercial biotech. In February 2024, the FDA granted accelerated approval to Amtagvi (lifileucel), making it the first cellular therapy for a metastatic solid tumor (per FDA, February 2024). The firm's structural differentiator lies in its vertically integrated model — owning both the proprietary TIL manufacturing throughput and the clinical infrastructure to run registration trials in-house. That architecture shields Amtagvi and its pipeline successors from the capacity bottlenecks that have constrained third-party-dependent cell therapy developers. The company remains independent, with no controlling parent entity and a board chaired by an independent director.